Category: Gabapentin

Gabapentin 600mg, 800mg – Zydus Pharmaceuticals (USA) Inc.

ZE 72 (Gabapentin 600 mg)

Pill with imprint ZE 72 is White, Elliptical/Oval and has been identified as Gabapentin 600 mg. It is supplied by Zydus Pharmaceuticals (USA) Inc.

Gabapentin is used in the treatment of postherpetic neuralgia; epilepsy and belongs to the drug class gamma-aminobutyric acid analogs. Risk cannot be ruled out during pregnancy. Gabapentin 600 mg is not a controlled substance under the Controlled Substances Act (CSA).

Gabapentin

Imprint
ZE 72
Strength
600 mg
Color
White
Shape
Elliptical/Oval
Availability
Prescription only
Drug Class
Gamma-aminobutyric acid analogs
Pregnancy Category
C – Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Zydus Pharmaceuticals (USA) Inc.
Inactive Ingredients
copovidone, low substituted hydroxypropyl cellulose, magnesium stearate, mannitol, poloxamer 407, povidone, magnesium silicate

Note: Inactive ingredients may vary.

Labelers / Repackagers

NDC Code Labeler / Repackager
68382-0204 Zydus Pharmaceuticals (USA) Inc.
68084-0797 (Discontinued) Amerisource Health Services
63739-0560 McKesson Packaging Services

ZE 71 (Gabapentin 800 mg)

Pill with imprint ZE 71 is White, Elliptical/Oval and has been identified as Gabapentin 800 mg. It is supplied by Zydus Pharmaceuticals (USA) Inc.

Gabapentin is used in the treatment of postherpetic neuralgia; epilepsy and belongs to the drug class gamma-aminobutyric acid analogs. Risk cannot be ruled out during pregnancy. Gabapentin 800 mg is not a controlled substance under the Controlled Substances Act (CSA).

Gabapentin

Imprint
ZE 71
Strength
800 mg
Color
White
Shape
Elliptical/Oval
Availability
Prescription only
Drug Class
Gamma-aminobutyric acid analogs
Pregnancy Category
C – Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Zydus Pharmaceuticals (USA) Inc.
Inactive Ingredients
copovidone, low substituted hydroxypropyl cellulose, magnesium stearate, mannitol, poloxamer 407, povidone, magnesium silicate

Note: Inactive ingredients may vary.

Labelers / Repackagers

NDC Code Labeler / Repackager
68382-0205 Zydus Pharmaceuticals (USA) Inc.
68084-0802 (Discontinued) Amerisource Health Services

Gabapentin 600 mg, 800mg – Solco Healthcare U.S., LLC

NT 150 (Gabapentin 600 mg)

Pill with imprint NT 150 is White, Elliptical/Oval and has been identified as Gabapentin 600 mg. It is supplied by Solco Healthcare U.S., LLC.

Gabapentin is used in the treatment of postherpetic neuralgia; epilepsy and belongs to the drug class gamma-aminobutyric acid analogs. Risk cannot be ruled out during pregnancy. Gabapentin 600 mg is not a controlled substance under the Controlled Substances Act (CSA).

Gabapentin

Imprint
NT 150
Strength
600 mg
Color
White
Shape
Elliptical/Oval
Availability
Prescription only
Drug Class
Gamma-aminobutyric acid analogs
Pregnancy Category
C – Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Solco Healthcare U.S., LLC
Manufacturer
ScieGen Pharmaceuticals, Inc.
National Drug Code (NDC)
43547-0332 (Discontinued)
Inactive Ingredients
copovidone, hydroxypropyl cellulose, magnesium stearate, mannitol, poloxamer 407, polyethylene glycol, polyvinyl alcohol, magnesium silicate, titanium dioxide

NT 151 – Gabapentin 800mg

Pill with imprint NT 151 is White, Elliptical/Oval and has been identified as Gabapentin 800 mg. It is supplied by Solco Healthcare U.S., LLC.

Gabapentin is used in the treatment of postherpetic neuralgia; epilepsy and belongs to the drug class gamma-aminobutyric acid analogs. Risk cannot be ruled out during pregnancy. Gabapentin 800 mg is not a controlled substance under the Controlled Substances Act (CSA).

Gabapentin

Imprint
NT 151
Strength
800 mg
Color
White
Shape
Elliptical/Oval
Availability
Prescription only
Drug Class
Gamma-aminobutyric acid analogs
Pregnancy Category
C – Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Solco Healthcare U.S., LLC
Manufacturer
ScieGen Pharmaceuticals, Inc.
National Drug Code (NDC)
43547-0333 (Discontinued)
Inactive Ingredients
copovidone, hydroxypropyl cellulose, magnesium stearate, mannitol, poloxamer 407, polyethylene glycol, polyvinyl alcohol, magnesium silicate

Gabapentin 600 mg, Gabapentin 800 mg – ScieGen Pharmaceuticals, Inc.

Pill with imprint SG 1 77 is White, Capsule-shape and has been identified as Gabapentin 600 mg. It is supplied by ScieGen Pharmaceuticals, Inc.

Gabapentin is used in the treatment of postherpetic neuralgia; epilepsy and belongs to the drug class gamma-aminobutyric acid analogs. Risk cannot be ruled out during pregnancy.

Gabapentin 600 mg is not a controlled substance under the Controlled Substances Act (CSA).

Gabapentin

Imprint
SG 1 77
Strength
600 mg
Color
White
Size
18.00 mm
Shape
Capsule-shape
Availability
Prescription only
Drug Class
Gamma-aminobutyric acid analogs
Pregnancy Category
C – Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
ScieGen Pharmaceuticals, Inc.
National Drug Code (NDC)
50228-0177
Inactive Ingredients
poloxamer 407, mannitol, magnesium stearate, magnesium silicate, copovidone, silicon dioxide, hypromelloses, titanium dioxide

Gabapentin 800mg

Gabapentin

Imprint
SG 1 78
Strength
800 mg
Color
White
Size
19.00 mm
Shape
Capsule-shape
Availability
Prescription only
Drug Class
Gamma-aminobutyric acid analogs
Pregnancy Category
C – Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
ScieGen Pharmaceuticals, Inc.
National Drug Code (NDC)
50228-0178
Inactive Ingredients
poloxamer 407, mannitol, magnesium stearate, magnesium silicate, copovidone, silicon dioxide, hypromelloses, titanium dioxide

Gabapentin 800mg , Gabapentin 600mg – Aurobindo Pharma USA, Inc.

Pill with imprint D 24 is White, Elliptical/Oval and has been identified as Gabapentin 600 mg. It is supplied by Aurobindo Pharma USA, Inc.

Gabapentin is used in the treatment of postherpetic neuralgia; epilepsy and belongs to the drug class gamma-aminobutyric acid analogs.

Risk cannot be ruled out during pregnancy. Gabapentin 600 mg is not a controlled substance under the Controlled Substances Act (CSA).

Gabapentin 600mg

Imprint
D 24
Strength
600 mg
Color
White
Size
17.00 mm
Shape
Elliptical/Oval
Availability
Prescription only
Drug Class
Gamma-aminobutyric acid analogs
Pregnancy Category
C – Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Aurobindo Pharma USA, Inc.
Inactive Ingredients
copovidone, corn starch, crospovidone, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, magnesium silicate

Note: Inactive ingredients may vary.

Labelers / Repackagers

NDC Code Labeler / Repackager
65862-0523 Aurobindo Pharma Limited
16714-0330 NorthStar Rx LLC

Gabapentin 800mg

D 25 (Gabapentin 800 mg)

Pill with imprint D 25 is White, Elliptical/Oval and has been identified as Gabapentin 800 mg. It is supplied by Aurobindo Pharma USA, Inc.

Gabapentin is used in the treatment of postherpetic neuralgia; epilepsy and belongs to the drug class gamma-aminobutyric acid analogs. Risk cannot be ruled out during pregnancy. Gabapentin 800 mg is not a controlled substance under the Controlled Substances Act (CSA).

Gabapentin

Imprint
D 25
Strength
800 mg
Color
White
Size
19.00 mm
Shape
Elliptical/Oval
Availability
Prescription only
Drug Class
Gamma-aminobutyric acid analogs
Pregnancy Category
C – Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Aurobindo Pharma USA, Inc.
Inactive Ingredients
copovidone, corn starch, crospovidone, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, magnesium silicate

Note: Inactive ingredients may vary.

Labelers / Repackagers

NDC Code Labeler / Repackager
65862-0524 Aurobindo Pharma Limited
16714-0332 NorthStar Rx LLC

 

Gabapentin 600mg, 800mg – Glenmark Pharmaceuticals Inc.

G 31 (Gabapentin 600 mg)

Pill with imprint G 31 is White, Elliptical/Oval and has been identified as Gabapentin 600 mg. It is supplied by Glenmark Generics Inc.

Gabapentin is used in the treatment of postherpetic neuralgia; epilepsy and belongs to the drug class gamma-aminobutyric acid analogs. Risk cannot be ruled out during pregnancy. Gabapentin 600 mg is not a controlled substance under the Controlled Substances Act (CSA).

Gabapentin

Imprint
G 31
Strength
600 mg
Color
White
Size
17.00 mm
Shape
Elliptical/Oval
Availability
Prescription only
Drug Class
Gamma-aminobutyric acid analogs
Pregnancy Category
C – Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Glenmark Generics Inc.
Inactive Ingredients
corn starch, copovidone, poloxamer 407, magnesium stearate, titanium dioxide, magnesium silicate, polysorbate 80, water

Note: Inactive ingredients may vary.

Labelers / Repackagers

NDC Code Labeler / Repackager
68462-0126 Glenmark Pharmaceuticals Inc.
54868-5219 (Discontinued) Physicians Total Care Inc. (repackager)
54569-5956 A-S Medication Solutions, LLC (repackager)
33261-0051 Aidarex Pharmacuticals, LLC (repackager)

G 13 (Gabapentin 800 mg)

Pill with imprint G 13 is White, Elliptical/Oval and has been identified as Gabapentin 800 mg. It is supplied by Glenmark Generics Inc.

Gabapentin is used in the treatment of postherpetic neuralgia; epilepsy and belongs to the drug class gamma-aminobutyric acid analogs. Risk cannot be ruled out during pregnancy. Gabapentin 800 mg is not a controlled substance under the Controlled Substances Act (CSA).

Gabapentin

Imprint
G 13
Strength
800 mg
Color
White
Size
19.00 mm
Shape
Elliptical/Oval
Availability
Prescription only
Drug Class
Gamma-aminobutyric acid analogs
Pregnancy Category
C – Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Glenmark Generics Inc.
Inactive Ingredients
corn starch, copovidone, poloxamer 407, magnesium stearate, titanium dioxide, magnesium silicate, polysorbate 80, water

Note: Inactive ingredients may vary.

Labelers / Repackagers

NDC Code Labeler / Repackager
68462-0127 Glenmark Pharmaceuticals Inc.
54868-5195 (Discontinued) Physicians Total Care Inc. (repackager)

Can I Take Gabapentin When I Take Other Medicines and Herbal Supplements ?

Some medicines may affect how gabapentin works or increase the chance of you having side effects.

Antacids are medicines that counteract (neutralise) the acid in your stomach to relieve indigestion and heartburn.

They come as a liquid or chewable tablets and can be bought from pharmacies and shops without a prescription.

When antacids are used

Antacids may help if you have:

    • indigestion
    • heartburn or acid reflux – also known as gastro-oesophageal reflux disease (GORD)
    • a stomach ulcer
    • gastritis (inflammation of the stomach lining)

They can quickly relieve your symptoms for a few hours. But they do not treat the underlying cause and long-term use is not recommended.

Common types of antacids

Many different types of antacid are available. Some are sold under a brand name and others are named after their main ingredient. Brands include Gaviscon (alginic acid) and Pepto-Bismol (bismuth subsalicylate).

Ingredients to look for include:

      • aluminium hydroxide
      • magnesium carbonate
      • magnesium trisilicate
      • magnesium hydroxide
      • calcium carbonate
      • sodium bicarbonate

Some antacids also contain other medicines, such as an alginate (which coats your gullet with a protective layer) and simeticone (which reduces flatulence).

Antacids can reduce the amount of gabapentin that the body takes in so it does not work as well. To stop this happening, if you need to take an antacid, take it at least 2 hours before or after your dose of gabapentin.

Tell your doctor if you’re taking any of these medicines before you start gabapentin treatment:

      • strong painkillers, such as morphine – these can make you very tired and dizzy when you start taking gabapentin
      • antidepressants, such as amitriptyline or fluoxetine
      • antipsychotic medicines for mental health problems like schizophrenia or bipolar disorder
      • a medicine to prevent malaria called mefloquine

Mixing gabapentin with herbal remedies or supplements

Taking herbal remedies and supplements that can make you feel dizzy or drowsy while you’re taking gabapentin could make these side effects worse.

Potential issues with herbal medicines

If you’re taking, or plan to take, any herbal medicines, be aware of the following:

    • They may cause problems if you’re taking other medicines. They could result in reduced or enhanced effects of the medicine, including potential side effects.
    • You may experience a bad reaction or side effects after taking a herbal medicine.
    • Not all herbal medicines are regulated. Remedies specially prepared for individuals don’t need a licence, and those manufactured outside the UK may not be subject to regulation.
    • Evidence for the effectiveness of herbal medicines is generally very limited. Although some people find them helpful, in many cases their use tends to be based on traditional use rather than scientific research.

Certain groups of people should be particularly wary of taking herbal medicines.

Who should avoid herbal medicines?

Taking a herbal medicine may not be suitable for:

    • people taking other medicines
    • people with serious health conditions, such as liver or kidney disease
    • people who are going to have surgery
    • pregnant or breastfeeding women
    • the elderly
    • children – as with all medicines, herbal medicines should be kept out of the sight and reach of children

Speak to your doctor or pharmacist for advice before trying a herbal medicine if you fall into one of these groups.

Are there any serious interactions with gabapentin and other medications?

Serious breathing problems can happen if you take gabapentin with drugs that cause severe sleepiness or decreased awareness. Some examples include narcotic opioids, anti-anxiety medicines, antidepressants, and antihistamines. If you are 65 years of age or older and/or have a condition that affects your lungs, such as chronic obstructive pulmonary disease (COPD), there is an increased risk for breathing problems. Watch for increased sleepiness or decreased breathing when you start taking gabapentin or when the dose is increased. Get help right away if you develop breathing problems.

Seek immediate medical attention if these symptoms develop:

    • Confusion.
    • Unusual dizziness or lightheadedness.
    • Slowed, shallow or trouble breathing.
    • Unresponsiveness (can’t wake up).
    • Bluish-colored or tinted skin, especially on lips, fingers or toes.

What other medications and products can interact with gabapentin?

Products that interact with gabapentin include:

    • Alcohol.
    • Antihistamine-containing cold, cough and allergy products.
    • Certain medicines for anxiety or sleep.
    • Certain medicines for depression, such as amitriptyline, fluoxetine and sertraline.
    • Certain medicines for seizures, such as phenobarbital and primidone.
    • Certain medicines for stomach problems. (Wait two hours after taking aluminum and magnesium-containing antacids before taking gabapentin.)
    • General anesthetics, local anesthetics, or muscle relaxants given before surgery.
    • Narcotic pain medicines.

Can I drink alcohol while taking gabapentin?

Avoid drinking alcohol while taking gabapentin. Drinking alcohol with gabapentin could increase sleepiness or dizziness.

Gabapentin Breastfeeding Warnings

Benefit should outweigh risk.

Excreted into human milk: Yes

Gabapentin and breastfeeding

If your doctor or health visitor says your baby is healthy, you can take gabapentin while breastfeeding. It’s important to keep taking gabapentin to keep you well.

Gabapentin passes into breast milk in small amounts. It has not been known to cause any side effects in breastfed babies.

If your baby is not feeding as well as usual, seems unusually sleepy, has a stomach upset, or if you have any other concerns about your baby, talk to your doctor, pharmacist, health visitor or midwife.

Gabapentin and fertility

There’s no evidence to suggest that taking gabapentin reduces fertility in either men or women. However, discuss your pregnancy plans with a doctor. They may wish to review your medicine and prescribe a higher dose of folic acid for you to take (5mg a day) before you become pregnant.

Speak to a pharmacist or your doctor before taking gabapentin if you’re trying to get pregnant.

Comments:
-The effects in the nursing infant are unknown.
-Limited information indicates that maternal doses up to 2.1 g daily produce relatively low levels in infant serum.
-Breastfed infants should be monitored for drowsiness, adequate weight gain, and developmental milestones, especially in younger, exclusively breastfed infants and when using combinations of anticonvulsant or psychotropic drugs.

You can not take Prescription for a long time, you need find a way to treat your pain without prescription. Exercising is the best way to relieve your pain. because exercising can enhance your immune system and increase your muscle strength and make your nerve strong.

 

Gabapentin, impotence and other problems?

I was just hoping that you might have the answer I am hoping for?

I started taking gabapentin 300mg twice a day, then 3 times a day, then 600mg twice a day then 3 times a day, now after 2 to 3 years later 800mg 3 times a day.

My doctor says it won’t cause erectile dysfunction but it started very soon after the 300mg 3 times a day. I tried Viagra and Cialis very little help. My wife is very displeased and sometimes thinks it is something to do with her. I know it has nothing to do with her as she is my bride of 24 years and my soul mate spirit. I have very bad pain that the gabapentin used to help with but it now seems it helps no more.

I would rather have my manhood back and my bride be happy and me than be in pain that just won’t go away. To get to the real question, how slowly should I get off the gabapentin and will I ever be able to get back to normal?

I will have to just have to tolerate the pain now that I have my diabetes under control. I rarely have to take my diabetes medicine but a few times a week because it makes my numbers to low and I black out when they get to low.

Usually 82 morning, 92 lunch, and 98 dinner. Any help will be greatly appreciated.

Answers:

Unfortunately gabapentin can cause impotence.

Side effects of the Urogenital System:

Infrequent: urinary tract infection, dysuria, impotence, urinary incontinence, vaginal moniliasis, breast pain, menstrual disorder, polyuria, urinary retention

Rare: cystitis, ejaculation abnormal, swollen penis, gynecomastia, nocturia, pyelonephritis, swollen scrotum, urinary frequency, urinary urgency, urine abnormality.

Talk to your doctor about coming off gabapentin and he/she could put you on some other medicine to help the pain. You don’t have to ween off gabapentin but please get your doctor to monitor you once you are off.

Cautions with other medicines

Some medicines may affect how gabapentin works or increase the chance of you having side effects.

Antacids can reduce the amount of gabapentin that the body takes in so it does not work as well. To stop this happening, if you need to take an antacid, take it at least 2 hours before or after your dose of gabapentin.

Tell your doctor if you’re taking any of these medicines before you start gabapentin treatment:

  • strong painkillers, such as morphine – these can make you very tired and dizzy when you start taking gabapentin
  • antidepressants, such as amitriptyline or fluoxetine
  • antipsychotic medicines for mental health problems like schizophrenia or bipolar disorder
  • a medicine to prevent malaria called mefloquine

Gabapentin Drug Interaction

Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Monitor therapy


Alizapride: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Aluminum Hydroxide: May decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after administration of antacids containing aluminum hydroxide or magnesium hydroxide. Consider therapy modification

Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). Avoid combination

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Consider therapy modification

Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Bromopride: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Avoid combination

Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Consider therapy modification

Cannabidiol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Cannabis: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Monitor therapy

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended. Monitor therapy

Dronabinol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Consider therapy modification

Esketamine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Consider therapy modification

HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Consider therapy modification

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Kava Kava: May enhance the adverse/toxic effect of CNS Depressants. Monitor therapy

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Monitor therapy

Magnesium Salts: May enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after use of a magnesium-containing antacid. Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used. Consider therapy modification

Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions. Monitor anticonvulsant concentrations and treatment response closely with concurrent use. Consider therapy modification

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established. Consider therapy modification

MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Monitor therapy

Mianserin: May diminish the therapeutic effect of Anticonvulsants. Monitor therapy

Minocycline: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Morphine (Systemic): Gabapentin may enhance the CNS depressant effect of Morphine (Systemic). Morphine (Systemic) may increase the serum concentration of Gabapentin. Monitor therapy

Nabilone: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Consider therapy modification

Orlistat: May decrease the serum concentration of Anticonvulsants. Monitor therapy

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Avoid combination

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Consider therapy modification

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Avoid combination

Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination. Consider therapy modification

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Monitor therapy

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Monitor therapy

Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Monitor therapy

Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated. Consider therapy modification

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Consider therapy modification

Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Consider therapy modification

Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Tetrahydrocannabinol and Cannabidiol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Avoid combination

Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Consider therapy modification

Gabapentin is used for Restless legs syndrome

Gabapentin in the management of restless legs syndrome (RLS) has been evaluated in small controlled trials, demonstrating benefits compared with placebo.

Restless legs syndrome (RLS) is a condition that causes an uncontrollable urge to move the legs, usually because of an uncomfortable sensation. It typically happens in the evening or nighttime hours when you’re sitting or lying down. Moving eases the unpleasant feeling temporarily.

Restless legs syndrome, also known as Willis-Ekbom disease, can begin at any age and generally worsens as you age. It can disrupt sleep, which interferes with daily activities.

Simple self-care steps and lifestyle changes may help relieve symptoms. Medications also help many people with RLS.

Gabapentin enacarbil is FDA-approved for the treatment of RLS .

The American Academy of Sleep Medicine (AASM) guidelines regarding RLS management consider gabapentin effective based on low-level evidence and note that patients with pain symptoms appeared to benefit most.

The benefit-risk ratio is unclear. The European Federation of Neurological Societies/European Neurological Society/European Sleep Research Society (EFNS/ENS/ESRS) Task Force guidelines consider gabapentin effective for short-term management and possibly effective for long-term management of RLS.

Additional study is needed to establish optimal dosing. Based on the International Restless Legs Syndrome Study Group, European Restless Legs Syndrome Study Group, and RLS Foundation (IRLSSG/EURLSSG/RLS-F) guidelines for the prevention and treatment of dopaminergic augmentation in restless legs syndrome, α2δ ligands (eg, gabapentin) are effective and should be considered for the initial treatment of patients with RLS due to their minimal risk of augmentation.

Additionally, patients who experience augmentation on dopaminergic agents may benefit from a switch to α2δ ligands (eg, gabapentin). However, the guidelines note that long-term studies are needed.